Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elena Nicod

Showing results (11-20 of 28) with videos related to

Pageof 3
Sort By:
Pharmacoeconomics|March 11, 2020
'Mapping' Health State Utility Values from Non-preference-Based Measures: A Systematic Literature Review in Rare DiseasesMichela Meregaglia, Amanda Whittal, Elena Nicod, et al.
Orphanet Journal of Rare Diseases|July 22, 2020
Are supplemental appraisal/reimbursement processes needed for rare disease treatments? An international comparison of country approachesElena Nicod, Amanda Whittal, Michael Drummond, et al.
International Journal of Technology Assessment in Health Care|May 28, 2021
Examining the impact of different country processes for appraising rare disease treatments: a case study analysisAmanda Whittal, Elena Nicod, Mike Drummond, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|July 18, 2017
Dealing with Uncertainty and Accounting for Social Value Judgments in Assessments of Orphan Drugs: Evidence from Four European CountriesElena Nicod, Karen Berg Brigham, Isabelle Durand-Zaleski, et al.
Health Policy (Amsterdam, Netherlands)|April 13, 2017
HTA programme response to the challenges of dealing with orphan medicinal products: Process evaluation in selected European countriesElena Nicod, Lieven Annemans, Anna Bucsics, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|October 29, 2021
Consideration of quality of life in the health technology assessments of rare disease treatmentsElena Nicod, Michela Meregaglia, Amanda Whittal, et al.
Retina (Philadelphia, Pa.)|May 30, 2013
Symptomatic vitreomacular adhesionTimothy L Jackson, Elena Nicod, Andrew Simpson, et al.
Retina (Philadelphia, Pa.)|September 16, 2016
PARS PLANA VITRECTOMY FOR DIABETIC MACULAR EDEMA: A Systematic Review, Meta-Analysis, and Synthesis of Safety LiteratureTimothy L Jackson, Elena Nicod, Aris Angelis, et al.
Global & Regional Health Technology Assessment|January 11, 2023
Price and reimbursement for orphan medicines and managed entry agreements: does Italy need a framework?Claudio Jommi, Antonio Addis, Nello Martini, et al.
BMC Health Services Research|September 30, 2015
Social and economic costs and health-related quality of life in non-institutionalised patients with cystic fibrosis in the United KingdomAris Angelis, Panos Kanavos, Julio López-Bastida, et al.
Pageof 3

Showing results (11-20 of 28) with videos related to

Sort By:
Pageof 3
Pharmacoeconomics|March 11, 2020
'Mapping' Health State Utility Values from Non-preference-Based Measures: A Systematic Literature Review in Rare DiseasesMichela Meregaglia, Amanda Whittal, Elena Nicod, et al.
Orphanet Journal of Rare Diseases|July 22, 2020
Are supplemental appraisal/reimbursement processes needed for rare disease treatments? An international comparison of country approachesElena Nicod, Amanda Whittal, Michael Drummond, et al.
International Journal of Technology Assessment in Health Care|May 28, 2021
Examining the impact of different country processes for appraising rare disease treatments: a case study analysisAmanda Whittal, Elena Nicod, Mike Drummond, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|July 18, 2017
Dealing with Uncertainty and Accounting for Social Value Judgments in Assessments of Orphan Drugs: Evidence from Four European CountriesElena Nicod, Karen Berg Brigham, Isabelle Durand-Zaleski, et al.
Health Policy (Amsterdam, Netherlands)|April 13, 2017
HTA programme response to the challenges of dealing with orphan medicinal products: Process evaluation in selected European countriesElena Nicod, Lieven Annemans, Anna Bucsics, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|October 29, 2021
Consideration of quality of life in the health technology assessments of rare disease treatmentsElena Nicod, Michela Meregaglia, Amanda Whittal, et al.
Retina (Philadelphia, Pa.)|May 30, 2013
Symptomatic vitreomacular adhesionTimothy L Jackson, Elena Nicod, Andrew Simpson, et al.
Retina (Philadelphia, Pa.)|September 16, 2016
PARS PLANA VITRECTOMY FOR DIABETIC MACULAR EDEMA: A Systematic Review, Meta-Analysis, and Synthesis of Safety LiteratureTimothy L Jackson, Elena Nicod, Aris Angelis, et al.
Global & Regional Health Technology Assessment|January 11, 2023
Price and reimbursement for orphan medicines and managed entry agreements: does Italy need a framework?Claudio Jommi, Antonio Addis, Nello Martini, et al.
BMC Health Services Research|September 30, 2015
Social and economic costs and health-related quality of life in non-institutionalised patients with cystic fibrosis in the United KingdomAris Angelis, Panos Kanavos, Julio López-Bastida, et al.
Pageof 3